These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 9515168)

  • 1. Compartmentalization of PDE-4 and cAMP-dependent protein kinase in neutrophils and macrophages during phagocytosis.
    Pryzwansky KB; Kidao S; Merricks EP
    Cell Biochem Biophys; 1998; 28(2-3):251-75. PubMed ID: 9515168
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Suppression of lipopolysaccharide-induced tumor necrosis factor-alpha generation from human peripheral blood monocytes by inhibitors of phosphodiesterase 4: interaction with stimulants of adenylyl cyclase.
    Seldon PM; Barnes PJ; Meja K; Giembycz MA
    Mol Pharmacol; 1995 Oct; 48(4):747-57. PubMed ID: 7476903
    [TBL] [Abstract][Full Text] [Related]  

  • 3. cAMP cascade (PKA, Epac, adenylyl cyclase, Gi, and phosphodiesterases) regulates myelin phagocytosis mediated by complement receptor-3 and scavenger receptor-AI/II in microglia and macrophages.
    Makranz C; Cohen G; Reichert F; Kodama T; Rotshenker S
    Glia; 2006 Mar; 53(4):441-8. PubMed ID: 16345030
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-time monitoring of phosphodiesterase inhibition in intact cells.
    Herget S; Lohse MJ; Nikolaev VO
    Cell Signal; 2008 Aug; 20(8):1423-31. PubMed ID: 18467075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential regulation of human monocyte-derived TNF alpha and IL-1 beta by type IV cAMP-phosphodiesterase (cAMP-PDE) inhibitors.
    Verghese MW; McConnell RT; Strickland AB; Gooding RC; Stimpson SA; Yarnall DP; Taylor JD; Furdon PJ
    J Pharmacol Exp Ther; 1995 Mar; 272(3):1313-20. PubMed ID: 7891349
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Upregulation of cAMP-specific PDE-4 activity following ligation of the TCR complex on thymocytes is blocked by selective inhibitors of protein kinase C and tyrosyl kinases.
    Michie AM; Rena G; Harnett MM; Houslay MD
    Cell Biochem Biophys; 1998; 28(2-3):161-85. PubMed ID: 9515165
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro down-regulation of antigen-induced IL-5 gene expression and protein production by cAMP-specific phosphodiesterase type 4 inhibitor.
    Foissier L; Lonchampt M; Cogé F; Canet E
    J Pharmacol Exp Ther; 1996 Sep; 278(3):1484-90. PubMed ID: 8819536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Type 4 cAMP phosphodiesterase (PDE4) inhibitors augment glucocorticoid-mediated apoptosis in B cell chronic lymphocytic leukemia (B-CLL) in the absence of exogenous adenylyl cyclase stimulation.
    Tiwari S; Dong H; Kim EJ; Weintraub L; Epstein PM; Lerner A
    Biochem Pharmacol; 2005 Feb; 69(3):473-83. PubMed ID: 15652238
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation and induction of cyclic AMP phosphodiesterase (PDE4) in rat pulmonary microvascular endothelial cells.
    Zhu B; Kelly J; Vemavarapu L; Thompson WJ; Strada SJ
    Biochem Pharmacol; 2004 Aug; 68(3):479-91. PubMed ID: 15242814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of chemotactic peptide-induced neutrophil adhesion to vascular endothelium by cAMP modulators.
    Derian CK; Santulli RJ; Rao PE; Solomon HF; Barrett JA
    J Immunol; 1995 Jan; 154(1):308-17. PubMed ID: 7995950
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A role for cyclic nucleotide phosphodiesterase 4 in regulation of the growth of human malignant melanoma cells.
    Narita M; Murata T; Shimizu K; Nakagawa T; Sugiyama T; Inui M; Hiramoto K; Tagawa T
    Oncol Rep; 2007 May; 17(5):1133-9. PubMed ID: 17390056
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Numerous distinct PKA-, or EPAC-based, signalling complexes allow selective phosphodiesterase 3 and phosphodiesterase 4 coordination of cell adhesion.
    Raymond DR; Wilson LS; Carter RL; Maurice DH
    Cell Signal; 2007 Dec; 19(12):2507-18. PubMed ID: 17884339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of cyclic-AMP on arginase activity by a murine macrophage cell line (RAW264.7) stimulated with lipopolysaccharide from Actinobacillus actinomycetemcomitans.
    Sosroseno W; Musa M; Ravichandran M; Fikri Ibrahim M; Bird PS; Seymour GJ
    Oral Microbiol Immunol; 2006 Dec; 21(6):347-52. PubMed ID: 17064391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of phosphodiesterase 4 in guinea-pig macrophages: multiple activities, association states and sensitivity to selective inhibitors.
    Kelly JJ; Barnes PJ; Giembycz MA
    Br J Pharmacol; 1998 May; 124(1):129-40. PubMed ID: 9630352
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interleukin-10 does not mediate the inhibitory effect of PDE-4 inhibitors and other cAMP-elevating drugs on lipopolysaccharide-induced tumors necrosis factor-alpha generation from human peripheral blood monocytes.
    Seldon PM; Barnes PJ; Giembycz MA
    Cell Biochem Biophys; 1998; 29(1-2):179-201. PubMed ID: 9631245
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modulation of cell adhesion molecule expression and function on human lung microvascular endothelial cells by inhibition of phosphodiesterases 3 and 4.
    Blease K; Burke-Gaffney A; Hellewell PG
    Br J Pharmacol; 1998 May; 124(1):229-37. PubMed ID: 9630364
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DSM-RX78, a new phosphodiesterase inhibitor, suppresses superoxide anion production in activated human neutrophils and attenuates hemorrhagic shock-induced lung injury in rats.
    Yu HP; Hsieh PW; Chang YJ; Chung PJ; Kuo LM; Hwang TL
    Biochem Pharmacol; 2009 Oct; 78(8):983-92. PubMed ID: 19540209
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of PDE3B augments PDE4 inhibitor-induced apoptosis in a subset of patients with chronic lymphocytic leukemia.
    Moon E; Lee R; Near R; Weintraub L; Wolda S; Lerner A
    Clin Cancer Res; 2002 Feb; 8(2):589-95. PubMed ID: 11839681
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential effects of specific phosphodiesterase isoenzyme inhibitors on bovine oocyte meiotic maturation.
    Thomas RE; Armstrong DT; Gilchrist RB
    Dev Biol; 2002 Apr; 244(2):215-25. PubMed ID: 11944932
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potentiation of erectile response and cAMP accumulation by combination of prostaglandin E1 and rolipram, a selective inhibitor of the type 4 phosphodiesterase (PDE 4).
    Bivalacqua TJ; Champion HC; Rajasekaran M; Sikka SC; Kadowitz PJ; Doherty PC; Hellstrom WJ
    J Urol; 1999 Nov; 162(5):1848-55. PubMed ID: 10524946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.